Bellevue Group’s Amneal Pharmaceuticals AMRX Stock Holding History

Bellevue Group’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,913	Closed	-$99.7K	–	156
2025 Q4	$99.7K	Hold	7,913	–	–	﹤0.01%	162
2025 Q3	$79.2K	Buy	+7,913	New	+$71K	﹤0.01%	144
2025 Q1	–	Sell	-100,414	Closed	-$795K	–	149
2024 Q4	$795K	Buy	100,414 +24,000	+31%	+$201K	0.02%	121
2024 Q3	$636K	Buy	76,414 +13,654	+22%	+$107K	0.01%	124
2024 Q2	$399K	Buy	62,760 +17,373	+38%	+$110K	0.01%	133
2024 Q1	$275K	Buy	45,387 +19,917	+78%	+$112K	﹤0.01%	147
2023 Q4	$155K	Buy	+25,470	New	+$113K	﹤0.01%	152
2020 Q1	–	Sell	-300,000	Closed	-$1.45M	–	217
2019 Q4	$1.45M	Buy	+300,000	New	+$1.04M	0.02%	144
2019 Q2	–	Sell	-100,000	Closed	-$1.42M	–	203
2019 Q1	$1.42M	Buy	100,000 +5,000	+5%	+$66.1K	0.08%	117
2018 Q4	$1.28M	Hold	95,000	–	–	0.08%	107
2018 Q3	$2.11M	Buy	95,000 +20,000	+27%	+$421K	0.13%	104
2018 Q2	$1.23M	Buy	+75,000	New	+$1.32M	0.1%	113

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Bellevue Group's AMRX Position: Q1 2026 in Review

Bellevue Group sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 7,913 shares — an estimated $99.7K sold.

Bellevue Group first reported a position in AMRX in Q2 2018 and held it in 12 quarters. The position peaked at $2.11M in Q3 2018. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Bellevue Group reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 7,913 Amneal Pharmaceuticals shares in Q1 2026, an estimated $99.7K.
Bellevue Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 12 quarters.
Bellevue Group's Amneal Pharmaceuticals position peaked at $2.11M in Q3 2018.
317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.